On January 15, Panion & BF Biotech announced that its innovative diagnostic product, the "FAIQ COVID-19 & Influenza A/B Antigen Rapid Test Kit," has officially obtained a medical device license from Taiwan’s Ministry of Health and Welfare. This triple antigen test kit enables rapid and accurate detection of influenza A, influenza B, and COVID-19, providing healthcare institutions with a convenient and efficient diagnostic tool.

Panion & BF Biotech noted that the market demand for rapid diagnostic products has surged amid the peak of the flu season. The company highlighted that the triple antigen test kit not only enhances its existing product portfolio but is also expected to drive double-digit revenue growth in its innovative diagnostics division. Furthermore, the FAIQ series has gained widespread recognition and acceptance from domestic healthcare institutions due to its high accuracy and ease of use.

In addition to meeting domestic market needs, Panion & BF Biotech plans to expand its diagnostic product offerings into overseas markets this year, contributing to additional revenue growth. This global expansion is expected to further solidify the company's influence in the international diagnostic product field.

Panion & BF Biotech emphasized its commitment to delivering high-quality, innovative medical solutions and to advancing diagnostic technologies, aiming to contribute to global public health.

Resource: 寶齡富錦呼吸道三合一抗原快速檢驗試劑